177 lu dota nocate 177 lu dota gastrin in metastatic medullary thyroid cancer l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
177 Lu-Dota-NOCate & 177 Lu-Dota-Gastrin in Metastatic Medullary Thyroid Cancer PowerPoint Presentation
Download Presentation
177 Lu-Dota-NOCate & 177 Lu-Dota-Gastrin in Metastatic Medullary Thyroid Cancer

Loading in 2 Seconds...

play fullscreen
1 / 11

177 Lu-Dota-NOCate & 177 Lu-Dota-Gastrin in Metastatic Medullary Thyroid Cancer - PowerPoint PPT Presentation


  • 158 Views
  • Uploaded on

177 Lu-Dota-NOCate & 177 Lu-Dota-Gastrin in Metastatic Medullary Thyroid Cancer. Clinic of Endocrinology, Inst. of Nuclear Medicine, University Hospital, Basel, CH For Questions contact: Beat Müller , happymiller@bigfoot.com Martin A. Walter , m.a.walter@gmx.net. Medullary Thyroid Cancer.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about '177 Lu-Dota-NOCate & 177 Lu-Dota-Gastrin in Metastatic Medullary Thyroid Cancer' - serge


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
177 lu dota nocate 177 lu dota gastrin in metastatic medullary thyroid cancer

177Lu-Dota-NOCate&177Lu-Dota-Gastrinin Metastatic Medullary Thyroid Cancer

Clinic of Endocrinology, Inst. of Nuclear Medicine, University Hospital, Basel, CH

For Questions contact:

Beat Müller, happymiller@bigfoot.com

Martin A. Walter, m.a.walter@gmx.net

medullary thyroid cancer
Medullary Thyroid Cancer

Treatment Options:

  • Surgery (first line)
  • To date no effective systemic treatment option
  • Radiation Therapy is not well defined
  • Treatment options with different Radiopeptides are currently evaluated
slide3
Aim

To assess the value of

177Lu-Dota-NOCate and 177Lu-Dota-Gastrin

in Imaging and Treatment of

Metastatic Medullary Thyroid Cancer

Ethically Approved (EKBB)

radiopeptides

Signal

177Lu

Target

Somatostatin/

CCK2-Receptor

Ligand

Somatostatin/

Gastrin-Analogs

Radiopeptides
magic bullet approach

Metastases

Tumor

Application

Distribution

Accumulation

„Magic Bullet“ Approach
receptor profile mtc
Receptor Profile (MTC)

EB Forssell-Aronsson. J Nucl Med2000;41:636–642

pilot patient dota noc ate
Pilot-Patient (Dota-NOC-ATE)

Specific

Tumor Uptake

(LN-metastesis)

p9581

♂, 63y

Metastised MTC

patients
Patients

Patients with progressive MTC

Exclusion criteria:

  • Karnofsky Performance Status < 50%
  • Refusion of a 1-year contraception
  • Pregnancy
  • Breast-feeding
  • Age<18
diagnostic scintigraphy
Diagnostic Scintigraphy
  • Scintigraphy + Dosimetry

(first compound, outpatient, 2d)

  • Scintigraphy + Dosimetry

(second compound, outpatient, 2d)

2 weeks later

  • Significant Accumulation

+ Favorable Biodistribution → Treatment

treatment
Treatment
  • Inpatient
  • 3 Days
  • Day 1: Injection of Radiopeptide

+ Amino Acid Infusion (Kidney Protection)

  • Day 2: Imaging
  • Day 3: Release of Patient